South Dakota Investment Council boosted its stake in Celgene Corporation (NASDAQ:CELG) by 1.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 229,530 shares of the biopharmaceutical company’s stock after purchasing an additional 4,330 shares during the period. South Dakota Investment Council’s holdings in Celgene Corporation were worth $29,809,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the business. Sowell Financial Services LLC increased its stake in Celgene Corporation by 0.5% in the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 13 shares during the period. South Texas Money Management Ltd. increased its stake in Celgene Corporation by 0.6% in the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 15 shares during the period. Flagship Harbor Advisors LLC increased its stake in Celgene Corporation by 0.9% in the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares during the period. Savant Capital LLC increased its stake in Celgene Corporation by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 20 shares during the period. Finally, Keel Point LLC increased its stake in Celgene Corporation by 0.9% in the 1st quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 28 shares during the period. 79.16% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “South Dakota Investment Council Has $29.81 Million Holdings in Celgene Corporation (CELG)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/13/south-dakota-investment-council-has-29-81-million-holdings-in-celgene-corporation-celg.html.

In other news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,227 shares of company stock valued at $2,843,956. Corporate insiders own 0.95% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) opened at $102.34 on Monday. The stock has a market capitalization of $80,574.02, a PE ratio of 15.99, a price-to-earnings-growth ratio of 0.79 and a beta of 1.79. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.58 earnings per share. equities research analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.

A number of equities analysts have commented on the company. Mizuho reaffirmed a “buy” rating on shares of Celgene Corporation in a research note on Friday, November 3rd. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $166.00 price objective (up from $163.00) on shares of Celgene Corporation in a research report on Monday, October 30th. Cantor Fitzgerald reiterated a “hold” rating and issued a $112.00 price objective on shares of Celgene Corporation in a research report on Monday, October 30th. J P Morgan Chase & Co set a $123.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Friday, October 27th. Finally, UBS AG cut their price objective on Celgene Corporation from $146.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the stock. Celgene Corporation presently has a consensus rating of “Buy” and an average target price of $139.64.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.